InvestorsHub Logo
Followers 145
Posts 27554
Boards Moderated 3
Alias Born 02/07/2004

Re: None

Wednesday, 11/08/2017 9:41:11 AM

Wednesday, November 08, 2017 9:41:11 AM

Post# of 3986

“I am excited about the progress we made recently,” said Moshe Manor, Protalix’s President and Chief Executive Officer. “We are no longer facing any debt issue or financing overhang. Moreover, with the recent strategic collaboration with Chiesi, not only did we secure a strong, experienced clinical and commercial partner, but we also meaningfully increased our capital resources, providing us with sufficient cash into 2020, irrespective of any milestone payments we are entitled to from Chiesi, increased revenues or from future partnerships. In addition, on the strategic front, we now have three novel and clinically differentiated product candidates in the clinic with potentially superior efficacy which provides us multiple shots at goal to realize significant value for our stockholders.”



https://finance.yahoo.com/news/protalix-biotherapeutics-inc-plx-announces-135547673.html
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent PLX News